Correlation Between Enfusion and ReposiTrak
Can any of the company-specific risk be diversified away by investing in both Enfusion and ReposiTrak at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enfusion and ReposiTrak into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enfusion and ReposiTrak, you can compare the effects of market volatilities on Enfusion and ReposiTrak and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enfusion with a short position of ReposiTrak. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enfusion and ReposiTrak.
Diversification Opportunities for Enfusion and ReposiTrak
-0.54 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Enfusion and ReposiTrak is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Enfusion and ReposiTrak in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ReposiTrak and Enfusion is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enfusion are associated (or correlated) with ReposiTrak. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ReposiTrak has no effect on the direction of Enfusion i.e., Enfusion and ReposiTrak go up and down completely randomly.
Pair Corralation between Enfusion and ReposiTrak
Given the investment horizon of 90 days Enfusion is expected to generate 0.85 times more return on investment than ReposiTrak. However, Enfusion is 1.18 times less risky than ReposiTrak. It trades about 0.06 of its potential returns per unit of risk. ReposiTrak is currently generating about -0.05 per unit of risk. If you would invest 1,052 in Enfusion on December 23, 2024 and sell it today you would earn a total of 58.00 from holding Enfusion or generate 5.51% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Enfusion vs. ReposiTrak
Performance |
Timeline |
Enfusion |
ReposiTrak |
Enfusion and ReposiTrak Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Enfusion and ReposiTrak
The main advantage of trading using opposite Enfusion and ReposiTrak positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enfusion position performs unexpectedly, ReposiTrak can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReposiTrak will offset losses from the drop in ReposiTrak's long position.Enfusion vs. ON24 Inc | Enfusion vs. Paycor HCM | Enfusion vs. E2open Parent Holdings | Enfusion vs. Braze Inc |
ReposiTrak vs. Eldorado Gold Corp | ReposiTrak vs. Griffon | ReposiTrak vs. Vinci Partners Investments | ReposiTrak vs. The Bank of |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |